A Multicenter, Double-blind, Active-controlled, Randomized, Parallel, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control
Latest Information Update: 20 Mar 2025
At a glance
- Drugs DA-2811 (Primary) ; Dapagliflozin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Dong-A ST
Most Recent Events
- 14 Mar 2025 Status changed from recruiting to completed.
- 15 Feb 2024 Planned End Date changed from 1 Jun 2024 to 1 Dec 2024.
- 15 Feb 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Dec 2024.